| In the face of the people’s demand for disease prevention,China’s population aging is intensifying,emerging infectious diseases,the chronic diseases incidence shows a rising trend,and the need to strengthen the prevention and control of traditional infectious diseases.It is necessary to accelerate the rapid and high-quality development of the pharmaceutical manufacturing industry.Although the overall development level of China’s pharmaceutical industry has achieved significant breakthroughs and significant achievements in industrial innovation during the 13 th Five Year Plan period,there are still problems such as insufficient reform and innovation efforts and insufficient technological innovation capabilities.It is still necessary to vigorously improve the innovation capacity of China’s pharmaceutical manufacturing industry,promote innovation driven transformation and high-quality development of China’s pharmaceutical industry.Guangdong Province is a major economic province in China,and the pharmaceutical manufacturing industry is one of emerging pillar industries that it has focused on developing in recent years.Only by mastering the actual situation of the technological innovation ability of the pharmaceutical manufacturing industry in Guangdong Province can we improve the technological innovation ability of the pharmaceutical manufacturing industry in a targeted manner and promote its progress towards high-quality development.Therefore,a comprehensive and objective evaluation of the technological innovation capability of Guangdong’s pharmaceutical manufacturing industry is of great significance for promoting the development of Guangdong’s pharmaceutical manufacturing industry.This paper takes the pharmaceutical manufacturing industry in Guangdong Province as the research object.Firstly,it summarizes the existing research results at home and abroad,and elaborates on relevant theories.Secondly,analyze the current situation of production and technological innovation of the pharmaceutical industry in Guangdong Province.Once again,based on the collaboration theory and relevant research results,the technological innovation capability of the pharmaceutical manufacturing industry is regarded as a collection of technological innovation input capability,technological innovation output capability,and technological innovation environment support capability.Constructs an evaluation index system based on existing research results,combined with relevant theories,and the VHSD-EM model is used to evaluate the technological innovation capability,input capability,output capability,environmental support capability and specific indicators of the pharmaceutical manufacturing industry in Guangdong Province.Meanwhile,compare and analyze the technological innovation capabilities of Guangdong’s pharmaceutical manufacturing industry with other provinces in China.On this basis,focus on analyzing the technological innovation capabilities of Guangdong Province,Jiangsu Province,Shandong Province,and Sichuan Province.Based on the above analysis,the results of this article are as follows:From 2010 to 2021,the production and operation level and technological innovation foundation of the pharmaceutical manufacturing industry in Guangdong Province are relatively leading among the 23 provinces in China.Its production and operation level is high,its investment strength in technological innovation funds is strong,and its environmental support status is good.In 2021,Guangdong Province ranked third in terms of the number of pharmaceutical manufacturing enterprises and the average number of workers employed,and fifth in terms of operating income and total profit,The technical innovation input index value,output index value,and environment index value rank fourth,with only the sales revenue of new products ranking fifth.From 2010 to 2021,the technological innovation capacity of the pharmaceutical manufacturing industry in Guangdong Province fluctuated around 2011 and2013,showing a stable upward trend overall,and has increased rapidly in recent years.Its environmental support capacity is very strong,and its input and output capabilities are weak.The scores of input capability and output capability have lowered the average score of technological innovation capability,but both have higher growth rate and annual growth rate.The annual average score of technological innovation ability from 2010 to 2021 was 0.27,and the score of technological innovation ability in 2021 was 0.5778,which was significantly higher than the annual average,5.81 times that of 2010.In 2021,the scores of its technological innovation input capacity,output capacity,and environmental support capacity were 0.1999,0.1207,and 0.2573,respectively.The imbalance between the three still exists.From 2010 to 2021,the insufficient internal R&D funds and domestic technology purchase funds led to a low average level of investment capacity,the insufficient sales revenue of new products led to a low average level of output capacity,and weak support from universities and technology markets led to a low average level of environmental support capacity.From 2010 to 2021,the ranking of technological innovation capabilities in the pharmaceutical manufacturing industry in Guangdong Province among 23 provinces was volatile,fluctuating from fifth place in 2010 to third place in 2021.In 2021,the score of technological innovation capability in the pharmaceutical manufacturing industry in Guangdong Province was 0.5778,with an average score of 0.2193 for 23 provinces.In 2021,the score of technological innovation capability in the pharmaceutical manufacturing industry in Guangdong Province was 0.5778,with an average score of 0.2193 for 23 provinces.The score of Guangdong Province was 2.63 times that of the average of 23 provinces,and its growth rate and annual average growth rate ranked first.From 2010 to 2021,although Guangdong Province ranked among the top in terms of technological innovation capabilities in the pharmaceutical manufacturing industry in the country,there is still a gap between Guangdong Province and Jiangsu Province and Shandong Province,which rank first or second all the year round.From2010 to 2021,Jiangsu Province and Shandong Province maintained a steady upward trend of development,while Guangdong Province declined in some years.The growth rate only began to accelerate in 2016,basically keeping pace with Jiangsu Province,slightly higher than Shandong Province.In 2021,Guangdong Province,Jiangsu Province,and Shandong Province scored 0.5778,0.6533,and 0.5846 in terms of technological innovation capability,respectively.There is still a gap between Guangdong Province and Jiangsu Province,while the gap with Shandong Province is narrowing.From 2010 to 2021,Guangdong Province significantly improved its investment capability and environmental support capability,leading Jiangsu Province and Shandong Province in terms of environmental support capability.The gap between Guangdong Province in terms of investment capability became smaller,but the gap in terms of output capability decreased slightly.At the same time,it is found that the input capability,output capability,and environmental support capability of Sichuan Province maintain steady growth and high coordination,which is worthy of reference for Guangdong Province.Finally,based on the above research results,this paper proposes the following suggestions to improve the technological innovation capability of the pharmaceutical manufacturing industry in Guangdong Province: Improving the production and operation status and providing support for the commercialization of technological innovation achievements.Broadening the financing channels and increasing investment in technological innovation.Strengthening the manpower investment and vigorously developing the innovative mode of "Industry-University-Research".Accelerating the digital transformation of the industry and building an intelligent pharmaceutical manufacturing industry.Improving the activity of the technology market and providing a way for innovation achievements to achieve economic benefits.Keeping open and compatible and integrating into domestic and foreign innovative industrial systems. |
PDF Full Text Request